Skip to main content

Table 6 Results of survival analysis showing association of variations with overall survival

From: Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients

Name Of Variant

# of Samples without mutation

# of samples with mutation

# of events in samples without mutation

# of events in samples with mutation

P value from Log Rank (SC) Test

Adjusted p-value

Hazard Ratio*

Gene Name

ENCODE annotation

dbSNP id

Impact

Location

chr6_160551093_T_G

44

15

8

7

0.007

0.59

3.723

SLC22A1

Heterochromatin; low signal

rs4646272

Modifier

Intron variant

chr11_62761161_C_T

42

17

7

8

0.019

0.59

3.161

SLC22A8

Repressed

rs2187384

Modifier

Intron variant, UTR3

chr4_69528597_A_G

51

8

11

4

0.024

0.59

3.462

UGT2B15

.

rs34073924

Modifier

Intron variant

chr7_2472429_C_A

53

6

11

4

0.040

0.59

3.124

CHST12

Transcription Elongation

rs3735099

Moderate, modifier

Missense variant; upstream gene variant

chr7_2472455_A_T

53

6

11

4

0.040

0.59

3.124

CHST12

Transcription Elongation

rs3735100

Moderate, modifier

Missense variant; upstream gene variant

  1. Variant name is defined as “ChromsomeNumber_Position_ReferenceAllele_AlternateAllele”
  2. The Hazard ratio was obtained from the Cox Proportional Hazards Test – indicates hazard value of having an event (death) in the mutation group compared to the non-mutation group